Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Corvus Pharmaceuticals, Inc. (CRVS) had Weighted-Average Shares Outstanding (Diluted) of 92.37M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-17.96M |
|
-- |
|
-- |
|
$19.30M |
|
$-19.30M |
|
$1.34M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
$-19.30M |
|
$-19.08M |
|
92.37M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
92.37M |
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$220.97M |
|
$0.83M |
|
$18.31M |
|
$239.27M |
|
$13.67M |
|
-- |
|
$0.27M |
|
$13.95M |
|
$225.33M |
|
$225.33M |
|
$225.33M |
|
84.12M |
|
| Cash Flow Statement Financials | |
$-25.77M |
|
$-150.81M |
|
$190.91M |
|
$4.58M |
|
$18.91M |
|
$14.33M |
|
$5.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-26.45M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-7.97% |
|
-7.97% |
|
-7.51% |
|
-7.97% |
|
$2.68 |
|
$-0.29 |
|
$-0.28 |
|